Vir Biotechnology, Inc. (VIR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$11.39-0.52%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VIR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Execute global strategic collaboration with Astellas to develop and commercialize VIR-5500 for metastatic prostate cancer, including Phase 1 dose expansions and planned pivotal Phase 3 trials.
Stated as a priority in 3 of last 3 quarters. The company closed a global strategic collaboration with Astellas by 2026-Q1 and initiated Phase 1 dose-expansion cohorts, with plans for pivotal Phase 3 trials in 2027. Cash and investments increased to approximately $1.01 billion by 2026-Q2, supported by $240 million upfront and $75 million equity payments from Astellas. The trajectory shows delivering progress consistent with management's stated collaboration and development plans.
“Closed global strategic collaboration with Astellas and initiated additional VIR-5500 Phase 1 dose-expansion cohorts.”
“Closed global strategic collaboration with Astellas and dosed first patients in Phase 1 dose-expansion cohorts.”
“Entered global strategic collaboration with Astellas to advance VIR-5500 for prostate cancer.”
Progress clinical development of elebsiran and tobevibart combination regimen for CHD, including Phase 2 SOLSTICE data presentation and ongoing Phase 3 ECLIPSE trials.
Stated as a priority in 3 of last 3 quarters. Management presented strong Phase 2 SOLSTICE data with 88% undetectable HDV RNA at Week 96 by 2026-Q2 and is progressing Phase 3 ECLIPSE trials with topline data expected in late 2026 and early 2027. The clinical development trajectory is delivering substantive progress consistent with management's stated goals.
“Presented Week 96 Phase 2 SOLSTICE data showing 88% undetectable HDV RNA in CHD patients.”
“Announced promising updated Phase 2 SOLSTICE data and upcoming presentation at EASL Congress.”
“Reported Phase 2 SOLSTICE data showing 77% undetectable HDV RNA at Week 72 and ongoing Phase 3 ECLIPSE trials.”
Maintain financial strength with cash, cash equivalents and investments sufficient to fund operations into the second half of 2028 through disciplined resource deployment and collaboration proceeds.
Stated as a priority in 5 of last 5 quarters. Cash, cash equivalents and investments increased from $809.3 million in 2026-Q1 to approximately $1.01 billion in 2026-Q2, supported by collaboration proceeds and disciplined resource deployment. Management consistently expects funding operations into the second half of 2028, indicating delivering progress on maintaining a strong financial position.
“Company expects cash, cash equivalents and investments to fund operations into the second half of 2028.”
“Company expects cash, cash equivalents and investments to fund operations into the second half of 2028.”
“Company expects cash, cash equivalents and investments to fund operations into the second quarter of 2028.”
“Cash runway extended into Q4 2027 due to licensing agreement and disciplined resource deployment.”
“Company expects cash, cash equivalents and investments to fund operations into mid-2027.”
Vir aims to extend its cash runway into the second half of 2028 through disciplined resource deployment.
Vir is committed to maintaining disciplined resource deployment to support its financial strategy.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Over the trailing year it converted 1.00x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
13 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.